JP2020534367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534367A5 JP2020534367A5 JP2020537858A JP2020537858A JP2020534367A5 JP 2020534367 A5 JP2020534367 A5 JP 2020534367A5 JP 2020537858 A JP2020537858 A JP 2020537858A JP 2020537858 A JP2020537858 A JP 2020537858A JP 2020534367 A5 JP2020534367 A5 JP 2020534367A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- subject
- growth factor
- fibroblast growth
- fat accumulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 230000002159 abnormal effect Effects 0.000 claims 10
- 238000009825 accumulation Methods 0.000 claims 10
- 206010008723 Chondrodystrophy Diseases 0.000 claims 9
- 208000008919 achondroplasia Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 231100000518 lethal Toxicity 0.000 claims 4
- 230000001665 lethal effect Effects 0.000 claims 4
- 206010053759 Growth retardation Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 210000004392 genitalia Anatomy 0.000 claims 3
- 231100000001 growth retardation Toxicity 0.000 claims 3
- 230000036244 malformation Effects 0.000 claims 3
- 230000009645 skeletal growth Effects 0.000 claims 3
- 210000003625 skull Anatomy 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 206010012559 Developmental delay Diseases 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 claims 2
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 claims 2
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 claims 2
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 claims 2
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims 2
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 2
- 102000003957 Fibroblast growth factor 9 Human genes 0.000 claims 2
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 208000025023 Cranial malformation Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000037093 Menstruation Disturbances Diseases 0.000 claims 1
- 206010027339 Menstruation irregular Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 241000219793 Trifolium Species 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 210000004507 artificial chromosome Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000004003 subcutaneous fat Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561140P | 2017-09-20 | 2017-09-20 | |
| US62/561,140 | 2017-09-20 | ||
| PCT/EP2018/075471 WO2019057820A1 (en) | 2017-09-20 | 2018-09-20 | ABNORMAL VISCERAL GREASE DEPOSITION TREATMENT USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534367A JP2020534367A (ja) | 2020-11-26 |
| JP2020534367A5 true JP2020534367A5 (OSRAM) | 2021-10-28 |
| JP7335247B2 JP7335247B2 (ja) | 2023-08-29 |
Family
ID=63878625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537858A Active JP7335247B2 (ja) | 2017-09-20 | 2018-09-20 | 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200297799A1 (OSRAM) |
| EP (1) | EP3684394A1 (OSRAM) |
| JP (1) | JP7335247B2 (OSRAM) |
| KR (1) | KR20200103621A (OSRAM) |
| CN (1) | CN111836634A (OSRAM) |
| AU (1) | AU2018335837A1 (OSRAM) |
| BR (1) | BR112020005459A2 (OSRAM) |
| CA (1) | CA3076396A1 (OSRAM) |
| IL (1) | IL273203A (OSRAM) |
| MX (1) | MX2020003114A (OSRAM) |
| PH (1) | PH12020550461A1 (OSRAM) |
| WO (1) | WO2019057820A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160002681A (ko) | 2013-01-16 | 2016-01-08 | 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) | 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 |
| HUE058734T2 (hu) | 2016-07-07 | 2022-09-28 | Pfizer | Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik |
| NL2020176B1 (en) * | 2017-12-22 | 2019-07-02 | Van Der Hoeven Horticultural Projects B V | Greenhouse |
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2022254319A1 (en) | 2021-06-01 | 2022-12-08 | Pfizer Inc. | Cell culture method for producing sfgfr3 polypeptide |
| KR20240109587A (ko) * | 2023-01-03 | 2024-07-11 | 서울대학교산학협력단 | Fgfr3 발현 또는 활성 억제제의 퇴행성 신경질환 치료 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002235202A1 (en) * | 2000-12-18 | 2002-07-01 | Gene Logic, Inc. | Treatment of bone disorders by modulation of fgfr3 |
| KR20160002681A (ko) * | 2013-01-16 | 2016-01-08 | 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) | 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 |
| SI3097122T1 (sl) * | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo |
| ES2843637T3 (es) | 2015-01-07 | 2021-07-19 | Pfizer | Señuelos FGFR3 solubles para tratar trastornos del crecimiento esquelético |
| HUE058734T2 (hu) * | 2016-07-07 | 2022-09-28 | Pfizer | Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik |
-
2018
- 2018-09-20 MX MX2020003114A patent/MX2020003114A/es unknown
- 2018-09-20 BR BR112020005459-3A patent/BR112020005459A2/pt not_active IP Right Cessation
- 2018-09-20 EP EP18788669.2A patent/EP3684394A1/en not_active Withdrawn
- 2018-09-20 WO PCT/EP2018/075471 patent/WO2019057820A1/en not_active Ceased
- 2018-09-20 CN CN201880061038.6A patent/CN111836634A/zh active Pending
- 2018-09-20 CA CA3076396A patent/CA3076396A1/en active Pending
- 2018-09-20 KR KR1020207009844A patent/KR20200103621A/ko not_active Ceased
- 2018-09-20 AU AU2018335837A patent/AU2018335837A1/en not_active Abandoned
- 2018-09-20 JP JP2020537858A patent/JP7335247B2/ja active Active
- 2018-09-20 US US16/649,208 patent/US20200297799A1/en not_active Abandoned
-
2020
- 2020-03-10 IL IL273203A patent/IL273203A/en unknown
- 2020-04-20 PH PH12020550461A patent/PH12020550461A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534367A5 (OSRAM) | ||
| CN112292144B (zh) | 激活素受体iib型变体及其使用方法 | |
| JP5274253B2 (ja) | 組織保護ペプチド及びその使用 | |
| AU2007215466B2 (en) | Long-acting polypeptides and methods of producing and administering same | |
| JP2021138740A (ja) | Ｇｉｐアゴニスト化合物及び方法 | |
| WO2011020319A1 (zh) | 调节血糖血脂的融合蛋白及其制备方法和应用 | |
| JPS63501567A (ja) | 生長因子 | |
| CN109306015A (zh) | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 | |
| US20180280480A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| BR122022025353B1 (pt) | Composição e uso de conjugado de derivado de oxintomodulina para a prevenção ou tratamento de hiperlipidemia, doença hepática gordurosa ou arteriosclerose | |
| EP2001903A2 (en) | Long-acting polypeptides and methods of producing and administering same | |
| CN105829339A (zh) | 胰高血糖素-glp-1-gip三重激动剂化合物 | |
| JP2003534384A (ja) | 神経保護性ペプチド | |
| JP2008500373A5 (OSRAM) | ||
| JP2019527053A (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| JP2019527053A5 (OSRAM) | ||
| CN109414474B (zh) | 肝脏、胆道和胰腺障碍的治疗 | |
| CN100413888C (zh) | 可溶性多肽 | |
| JPWO2021021606A5 (OSRAM) | ||
| JP6232630B2 (ja) | 骨系統疾患治療薬及びその用途 | |
| EA019498B1 (ru) | Аналоги нейропептида y, содержащие по меньшей мере одну замену на синтетическую аминокислоту | |
| JP2002345468A5 (OSRAM) | ||
| JPH11506337A (ja) | 骨刺激因子 | |
| JP7637435B2 (ja) | 長時間作用型アドレノメデュリン誘導体の製造方法 | |
| JPH05504069A (ja) | タイプ１ インターフェロン由来の新規変異体、それらの製造方法及びそれらの適用 |